Skip to content
lifestyle.smarttalksuccess.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Aprea Therapeutics
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
August 12, 2026
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
July 30, 2026
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
June 1, 2026
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 13, 2026
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
May 4, 2026
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
May 2, 2026
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
May 2, 2026
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
May 2, 2026
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 16, 2026
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
February 18, 2026
1
2
Next Page
→